An Update of the Appropriate Treatment Strategies in Anaplastic Thyroid Cancer: A Population-Based Study of 735 Patients

Background. Anaplastic thyroid cancer (ATC) responds poorly to conventional therapies and requires a multidisciplinary approach to manage. The aim of the current study is to explore whether aggressive treatment is beneficial, especially the appropriate extent of surgery in ATC. Methods. Patients dia...

Full description

Saved in:
Bibliographic Details
Main Authors: Nai-si Huang, Xiao Shi, Bo-wen Lei, Wen-jun Wei, Zhong-wu Lu, Peng-cheng Yu, Yu Wang, Qing-hai Ji, Yu-long Wang
Format: Article
Language:English
Published: Wiley 2019-01-01
Series:International Journal of Endocrinology
Online Access:http://dx.doi.org/10.1155/2019/8428547
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832552225791016960
author Nai-si Huang
Xiao Shi
Bo-wen Lei
Wen-jun Wei
Zhong-wu Lu
Peng-cheng Yu
Yu Wang
Qing-hai Ji
Yu-long Wang
author_facet Nai-si Huang
Xiao Shi
Bo-wen Lei
Wen-jun Wei
Zhong-wu Lu
Peng-cheng Yu
Yu Wang
Qing-hai Ji
Yu-long Wang
author_sort Nai-si Huang
collection DOAJ
description Background. Anaplastic thyroid cancer (ATC) responds poorly to conventional therapies and requires a multidisciplinary approach to manage. The aim of the current study is to explore whether aggressive treatment is beneficial, especially the appropriate extent of surgery in ATC. Methods. Patients diagnosed with ATC from 2004 to 2014 were identified from the Surveillance, Epidemiology, and End Results (SEER) database and included in our study. Results. A total of 735 ATC patients were identified. The two-year overall survival (OS) rates for stage IVA, IVB, and IVC patients were 36.5%, 15.6%, and 1.4%, respectively. By directly comparing eight treatment modalities, we found that surgery+radiotherapy RT±chemotherapy was the most effective treatment strategy. surgery+chemotherapy and RT+chemotherapy had comparable results (hazard ratio HR=1.461, 95% confidential interval (CI): 0.843-2.531, P=0.177). Multivariate Cox regression analysis also showed increased mortality risk in patients with increased age (HR=1.022, P<0.001), tumor extension to adjacent structures (HR=1.649, P=0.013), and distant metastasis (HR=2.041, P<0.001), while surgery+RT (HR=0.600, P=0.004) and chemotherapy (HR=0.692, P=0.010) were independently associated with improved OS. Further analysis revealed that patients undergoing total/near-total thyroidectomy (TT) had superior OS to those receiving less than TT (P<0.001). In subgroup analysis, the benefit of TT remained significant in patients with tumors larger than 4.0 cm (HR=0.776, 95% CI: 0.469-0.887, P=0.007), with adjacent structure extension (HR=0.642, 95% CI: 0.472-0.877, P=0.005), including trachea and major vessels, but not in patients with early phase local disease such as tumor≤4.0 cm or tumor within the thyroid or with minimal extrathyroidal extension. Patients with very locally advanced disease or distant metastasis could not benefit from TT as well. Conclusions. In operable cases, surgery+RT±chemotherapy was the optimal treatment modality. Otherwise, RT+chemotherapy was the appropriate strategy. However, TT was not beneficial for very early stage or metastatic ATC.
format Article
id doaj-art-555ecac133ff42a2b940639a11cc437e
institution Kabale University
issn 1687-8337
1687-8345
language English
publishDate 2019-01-01
publisher Wiley
record_format Article
series International Journal of Endocrinology
spelling doaj-art-555ecac133ff42a2b940639a11cc437e2025-02-03T05:59:18ZengWileyInternational Journal of Endocrinology1687-83371687-83452019-01-01201910.1155/2019/84285478428547An Update of the Appropriate Treatment Strategies in Anaplastic Thyroid Cancer: A Population-Based Study of 735 PatientsNai-si Huang0Xiao Shi1Bo-wen Lei2Wen-jun Wei3Zhong-wu Lu4Peng-cheng Yu5Yu Wang6Qing-hai Ji7Yu-long Wang8Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, ChinaDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, ChinaDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, ChinaDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, ChinaDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, ChinaDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, ChinaDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, ChinaDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, ChinaDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, ChinaBackground. Anaplastic thyroid cancer (ATC) responds poorly to conventional therapies and requires a multidisciplinary approach to manage. The aim of the current study is to explore whether aggressive treatment is beneficial, especially the appropriate extent of surgery in ATC. Methods. Patients diagnosed with ATC from 2004 to 2014 were identified from the Surveillance, Epidemiology, and End Results (SEER) database and included in our study. Results. A total of 735 ATC patients were identified. The two-year overall survival (OS) rates for stage IVA, IVB, and IVC patients were 36.5%, 15.6%, and 1.4%, respectively. By directly comparing eight treatment modalities, we found that surgery+radiotherapy RT±chemotherapy was the most effective treatment strategy. surgery+chemotherapy and RT+chemotherapy had comparable results (hazard ratio HR=1.461, 95% confidential interval (CI): 0.843-2.531, P=0.177). Multivariate Cox regression analysis also showed increased mortality risk in patients with increased age (HR=1.022, P<0.001), tumor extension to adjacent structures (HR=1.649, P=0.013), and distant metastasis (HR=2.041, P<0.001), while surgery+RT (HR=0.600, P=0.004) and chemotherapy (HR=0.692, P=0.010) were independently associated with improved OS. Further analysis revealed that patients undergoing total/near-total thyroidectomy (TT) had superior OS to those receiving less than TT (P<0.001). In subgroup analysis, the benefit of TT remained significant in patients with tumors larger than 4.0 cm (HR=0.776, 95% CI: 0.469-0.887, P=0.007), with adjacent structure extension (HR=0.642, 95% CI: 0.472-0.877, P=0.005), including trachea and major vessels, but not in patients with early phase local disease such as tumor≤4.0 cm or tumor within the thyroid or with minimal extrathyroidal extension. Patients with very locally advanced disease or distant metastasis could not benefit from TT as well. Conclusions. In operable cases, surgery+RT±chemotherapy was the optimal treatment modality. Otherwise, RT+chemotherapy was the appropriate strategy. However, TT was not beneficial for very early stage or metastatic ATC.http://dx.doi.org/10.1155/2019/8428547
spellingShingle Nai-si Huang
Xiao Shi
Bo-wen Lei
Wen-jun Wei
Zhong-wu Lu
Peng-cheng Yu
Yu Wang
Qing-hai Ji
Yu-long Wang
An Update of the Appropriate Treatment Strategies in Anaplastic Thyroid Cancer: A Population-Based Study of 735 Patients
International Journal of Endocrinology
title An Update of the Appropriate Treatment Strategies in Anaplastic Thyroid Cancer: A Population-Based Study of 735 Patients
title_full An Update of the Appropriate Treatment Strategies in Anaplastic Thyroid Cancer: A Population-Based Study of 735 Patients
title_fullStr An Update of the Appropriate Treatment Strategies in Anaplastic Thyroid Cancer: A Population-Based Study of 735 Patients
title_full_unstemmed An Update of the Appropriate Treatment Strategies in Anaplastic Thyroid Cancer: A Population-Based Study of 735 Patients
title_short An Update of the Appropriate Treatment Strategies in Anaplastic Thyroid Cancer: A Population-Based Study of 735 Patients
title_sort update of the appropriate treatment strategies in anaplastic thyroid cancer a population based study of 735 patients
url http://dx.doi.org/10.1155/2019/8428547
work_keys_str_mv AT naisihuang anupdateoftheappropriatetreatmentstrategiesinanaplasticthyroidcancerapopulationbasedstudyof735patients
AT xiaoshi anupdateoftheappropriatetreatmentstrategiesinanaplasticthyroidcancerapopulationbasedstudyof735patients
AT bowenlei anupdateoftheappropriatetreatmentstrategiesinanaplasticthyroidcancerapopulationbasedstudyof735patients
AT wenjunwei anupdateoftheappropriatetreatmentstrategiesinanaplasticthyroidcancerapopulationbasedstudyof735patients
AT zhongwulu anupdateoftheappropriatetreatmentstrategiesinanaplasticthyroidcancerapopulationbasedstudyof735patients
AT pengchengyu anupdateoftheappropriatetreatmentstrategiesinanaplasticthyroidcancerapopulationbasedstudyof735patients
AT yuwang anupdateoftheappropriatetreatmentstrategiesinanaplasticthyroidcancerapopulationbasedstudyof735patients
AT qinghaiji anupdateoftheappropriatetreatmentstrategiesinanaplasticthyroidcancerapopulationbasedstudyof735patients
AT yulongwang anupdateoftheappropriatetreatmentstrategiesinanaplasticthyroidcancerapopulationbasedstudyof735patients
AT naisihuang updateoftheappropriatetreatmentstrategiesinanaplasticthyroidcancerapopulationbasedstudyof735patients
AT xiaoshi updateoftheappropriatetreatmentstrategiesinanaplasticthyroidcancerapopulationbasedstudyof735patients
AT bowenlei updateoftheappropriatetreatmentstrategiesinanaplasticthyroidcancerapopulationbasedstudyof735patients
AT wenjunwei updateoftheappropriatetreatmentstrategiesinanaplasticthyroidcancerapopulationbasedstudyof735patients
AT zhongwulu updateoftheappropriatetreatmentstrategiesinanaplasticthyroidcancerapopulationbasedstudyof735patients
AT pengchengyu updateoftheappropriatetreatmentstrategiesinanaplasticthyroidcancerapopulationbasedstudyof735patients
AT yuwang updateoftheappropriatetreatmentstrategiesinanaplasticthyroidcancerapopulationbasedstudyof735patients
AT qinghaiji updateoftheappropriatetreatmentstrategiesinanaplasticthyroidcancerapopulationbasedstudyof735patients
AT yulongwang updateoftheappropriatetreatmentstrategiesinanaplasticthyroidcancerapopulationbasedstudyof735patients